Glazer Capital LLC’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Glazer Capital LLC’s Portfolio DMAAR Stock Details DMAAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-297,475	Closed	-$18K	–	621
2026 Q1	$18K	Sell	297,475 -239,377	-45%	-$25.4K	﹤0.01%	439
2025 Q4	$101K	Sell	536,852 -51,448	-9%	-$9.98K	﹤0.01%	281
2025 Q3	$128K	Sell	588,300 -711,700	-55%	-$132K	﹤0.01%	224
2025 Q2	$156K	Hold	1,300,000	–	–	0.01%	171
2025 Q1	$169K	Buy	+1,300,000	New	+$183K	0.01%	135

Other funds holding DMAAR

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Glazer Capital LLC's DMAAR Position: Q2 2026 in Review

Glazer Capital LLC sold out of Drugs Made In America Acquisition Corp Rights (DMAAR) in Q2 2026, closing a stake of 297,475 shares — an estimated $18K sold.

Glazer Capital LLC first reported a position in DMAAR in Q1 2025 and held it in 5 quarters. The position peaked at $169K in Q1 2025. 28 funds tracked by Wall St. Rank hold DMAAR as of Q2 2026.

Glazer Capital LLC reported no remaining Drugs Made In America Acquisition Corp Rights position as of Q2 2026 after selling out during the quarter.
Glazer Capital LLC sold 297,475 Drugs Made In America Acquisition Corp Rights shares in Q2 2026, an estimated $18K.
Glazer Capital LLC first reported a position in Drugs Made In America Acquisition Corp Rights in Q1 2025 and held it in 5 quarters.
Glazer Capital LLC's Drugs Made In America Acquisition Corp Rights position peaked at $169K in Q1 2025.
28 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q2 2026.

Based on Glazer Capital LLC's 13F filing for Q2 2026, filed 17 Aug 2026.